Philip Serlin, BioLineRx CEO
September 12, 2023 07:18 AM EDTUpdated 09:13 AM
Pharma
FDA+

Bi­o­Lin­eRx’s Aphex­da ap­proved to aid stem cell trans­plants for mul­ti­ple myelo­ma pa­tients

Nicole DeFeudis

Editor

Au­tol­o­gous stem cell trans­plan­ta­tion (AS­CT) is part of the stan­dard of care for pa­tients with mul­ti­ple myelo­ma. It’s a process in which a pa­tient’s own …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

A service from the Financial Times